Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101
LIN, Thomas S, DONOHUE, Kathleen A, BYRD, John C, LUCAS, Margaret S, HOKE, Eva E, BENGTSON, Elizabeth M, RAI, Kanti R, ATKINS, James N, LINK, Brian K, LARSON, Richard A
Published in Journal of clinical oncology (10.10.2010)
Published in Journal of clinical oncology (10.10.2010)
Get full text
Journal Article
Computed Tomography Scans Do Not Improve the Predictive Power of 1996 National Cancer Institute–Sponsored Working Group Chronic Lymphocytic Leukemia Response Criteria
BLUM, Kristie A, YOUNG, Donn, BROERING, Sarah, LUCAS, Margaret S, FISCHER, Beth, LIN, Thomas S, GREVER, Michael R, BYRD, John C
Published in Journal of clinical oncology (10.12.2007)
Published in Journal of clinical oncology (10.12.2007)
Get full text
Journal Article
Phase I Study of Low-Dose Interleukin-2, Fludarabine, and Cyclophosphamide for Previously Untreated Indolent Lymphoma and Chronic Lymphocytic Leukemia
KASAMON, Yvette L, FLINN, Ian W, GREVER, Michael R, DIEHL, Louis F, GARRETT-MAYER, Elizabeth, GOODMAN, Steven N, LUCAS, Margaret S, BYRD, John C
Published in Clinical cancer research (01.12.2005)
Published in Clinical cancer research (01.12.2005)
Get full text
Journal Article
Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists
Koenig, Kristin L., Huang, Ying, Dotson, Emily K., Sheredy, Shane, Bhat, Seema A., Byrd, John C., Desmond, Emily, Ford, Jill, Iarocci, Shauna, Jones, Jeffrey A., Lucas, Margaret S., Moran, Mollie E., Wiczer, Tracy E., Woyach, Jennifer A., Awan, Farrukh T., Rogers, Kerry A.
Published in Blood advances (13.10.2020)
Published in Blood advances (13.10.2020)
Get full text
Journal Article
Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity
Byrd, J C, Murphy, T, Howard, R S, Lucas, M S, Goodrich, A, Park, K, Pearson, M, Waselenko, J K, Ling, G, Grever, M R, Grillo-Lopez, A J, Rosenberg, J, Kunkel, L, Flinn, I W
Published in Journal of clinical oncology (15.04.2001)
Published in Journal of clinical oncology (15.04.2001)
Get full text
Journal Article
Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma
Awan, Farrukh T, Flynn, Joseph M, Jones, Jeffrey A, Andritsos, Leslie A, Maddocks, Kami J, Sass, Ellen J, Lucas, Margaret S, Chase, Weihong, Waymer, Sharon, Ling, Yonghua, Jiang, Yao, Phelps, Mitch A, Byrd, John C, Lucas, David M, Woyach, Jennifer A
Published in Leukemia & lymphoma (03.10.2015)
Published in Leukemia & lymphoma (03.10.2015)
Get full text
Journal Article
FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia
Lin, Thomas S., Flinn, Ian W., Modali, Rama, Lehman, Teresa A., Webb, Jennifer, Waymer, Sharon, Moran, Mollie E., Lucas, Margaret S., Farag, Sherif S., Byrd, John C.
Published in Blood (01.01.2005)
Published in Blood (01.01.2005)
Get full text
Journal Article
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia
Lin, Thomas S., Stock, Wendy, Xu, Huiping, Phelps, Mitch A., Lucas, Margaret S., Guster, Sara K., Briggs, Bruce R., Cheney, Carolyn, Porcu, Pierluigi, Flinn, Ian W., Grever, Michael R., Dalton, James T., Byrd, John C.
Published in Leukemia & lymphoma (01.12.2009)
Published in Leukemia & lymphoma (01.12.2009)
Get full text
Journal Article
Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia
Lin, Thomas S., Naumovski, Louie, Lecane, Philip S., Lucas, Margaret S., Moran, Mollie E., Cheney, Carolyn, Lucas, David M., Phan, See-Chun, Miller, Richard A., Byrd, John C.
Published in Leukemia & lymphoma (01.12.2009)
Published in Leukemia & lymphoma (01.12.2009)
Get full text
Journal Article
Extended Follow up of a Phase 2 Study of Early Intervention with Lenalidomide in Patients with High-Risk Chronic Lymphocytic Leukemia
Rogers, Kerry A, Zhao, Qiuhong, Bhat, Seema A, Byrd, John C., Grantier, Cara, Grever, Michael R., Hoffman, Corinne, Kittai, Adam S, Lozanski, Gerard, Lucas, Margaret S., Rike, Lindsey, Thangavadivel, Shanmugapriya, Carson III, William E., Woyach, Jennifer A.
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
Treatment of CLL-Associated Autoimmune Cytopenias and Outcomes in a Single Institution Cohort Study
Esplin, Isaac, Huang, Ying, Bhat, Seema A., Grantier, Cara, Grever, Michael R., Hoffman, Corinne, Kittai, Adam S, Lucas, Margaret S., Moran, Mollie E., Reid, Mark, Suresh, Swetha, Woyach, Jennifer A., Rogers, Kerry A.
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL
Woyach, Jennifer A., Guinn, Daphne, Ruppert, Amy S., Blachly, James S., Lozanski, Arletta, Heerema, Nyla A., Zhao, Weiqiang, Coleman, Joshua, Jones, Daniel, Abruzzo, Lynne V., Gordon, Amber, Mantel, Rose, Smith, Lisa L., McWhorter, Samantha, Davis, Melanie, Doong, Tzyy-Jye, Ny, Fan, Lucas, Margaret S., Chase, Weihong, Jones, Jeffrey, Flynn, Joseph M., Maddocks, Kami J., Jaglowski, Samantha, Andritsos, Leslie A., Awan, Farrukh T., Blum, Kristie, Grever, Michael R., Lozanski, Gerard, Byrd, John C., Johnson, Amy J.
Published in Blood (02.12.2016)
Published in Blood (02.12.2016)
Get full text
Journal Article
Consolidation Therapy with Subcutaneous (SC) Alemtuzumab After Fludarabine and Rituximab (FR) Induction Therapy Improves the Complete Response (CR) Rate in Chronic Lymphocytic Leukemia (CLL) and Eradicates Minimal Residual Disease (MRD) but Is Associated with Severe Infectious Toxicity: Final Analysis of CALGB Study 10101
Lin, Thomas S, Donohue, Kathleen A, Byrd, John C., Lucas, Margaret S, Hoke, Eva, Bengtson, Elizabeth M, Atkins, James N, Link, Brian K, Rai, Kanti R, Larson, Richard A
Published in Blood (20.11.2009)
Published in Blood (20.11.2009)
Get full text
Journal Article
A Phase I/II Study of Etanercept and Rituximab in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Woyach, Jennifer A, Lin, Thomas S, Lucas, Margaret S, Heerema, Nyla, Moran, Mollie E., Cheney, Carolyn, Lucas, David M., Wei, Lai, Caligiuri, Michael A., Byrd, John C.
Published in Leukemia (19.02.2009)
Published in Leukemia (19.02.2009)
Get full text
Journal Article
A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin's Lymphoma
Blum, Kristie A., Baiocchi, Robert A., Alinari, Lapo, Lin, Thomas S., Porcu, Pierluigi, Jones, Jeffrey, Flynn, Joseph, Hicks, William, Lucas, Margaret S., Wei, Lai, Johnston, Jeffrey S., Byrd, John C.
Published in Blood (16.11.2008)
Published in Blood (16.11.2008)
Get full text
Journal Article
Consolidation Therapy with Subcutaneous (SC) Alemtuzumab Results in Severe Infectious Toxicity in Previously Untreated CLL Patients Who Achieve a Complete Response (CR) after Fludarabine and Rituximab (FR) Induction Therapy: Interim Safety Analysis of the CALGB Study 10101
Lin, Thomas S., Donohue, Kathleen A., Lucas, Margaret S., Byrd, John C., Bengtson, Elizabeth M., Peterson, Bercedis L., Larson, Richard A.
Published in Blood (16.11.2007)
Published in Blood (16.11.2007)
Get full text
Journal Article
The Addition of CT Scans to NCI-96 Chronic Lymphocytic Leukemia (CLL) Response Criteria Fails To Improve the Predictive Power of Complete Response (CR) and Partial Response (PR) as Assessed by Improvement in Progression-Free (PFS) and Overall Survival (OS)
Blum, Kristie A., Young, Donn, Broering, Sarah, Lucas, Margaret S., Lin, Thomas S., Grever, Michael R., Byrd, John C.
Published in Blood (16.11.2006)
Published in Blood (16.11.2006)
Get full text
Journal Article
Excessive Neurotoxicity in a Phase II Trial of Combined Bortezomib and Rituximab in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin's Lymphoma
Blum, Kristie A., Lucas, Margaret S., Johnston, Jeffrey S., Dalton, James, Young, Donn, Baiocchi, Robert A., Lin, Thomas S., Porcu, Pierluigi, Byrd, John C.
Published in Blood (16.11.2006)
Published in Blood (16.11.2006)
Get full text
Journal Article
A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities
Lin, Thomas S., Lucas, Margaret S., Heerema, Nyla A., Matkovich, Jennifer J., Moran, Mollie E., Cheney, Carolyn, Lucas, David M., Young, Donn C., Caligiuri, Michael A., Grever, Michael R., Byrd, John C.
Published in Blood (16.11.2006)
Published in Blood (16.11.2006)
Get full text
Journal Article